Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBT Margin (2023 - 2025)

CG Oncology (CGON) has disclosed EBT Margin for 3 consecutive years, with 1776.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 519782.0% year-over-year to 1776.74%, compared with a TTM value of 3981.26% through Dec 2025, up 374850.0%, and an annual FY2025 reading of 3981.26%, up 374850.0% over the prior year.
  • EBT Margin was 1776.74% for Q4 2025 at CG Oncology, up from 2623.53% in the prior quarter.
  • Across five years, EBT Margin topped out at 1776.74% in Q4 2025 and bottomed at 1655100.0% in Q4 2023.
  • Average EBT Margin over 3 years is 193560.54%, with a median of 12005.3% recorded in 2024.
  • The sharpest move saw EBT Margin surged 164812544bps in 2024, then crashed -6306403bps in 2025.
  • Year by year, EBT Margin stood at 1655100.0% in 2023, then skyrocketed by 100bps to 6974.56% in 2024, then surged by 75bps to 1776.74% in 2025.
  • Business Quant data shows EBT Margin for CGON at 1776.74% in Q4 2025, 2623.53% in Q3 2025, and 66263.46% in Q1 2025.